Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

12.75 -0.08 (-0.62%)
Streaming Delayed Price Updated: 11:58 AM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 401,810
Open 12.80
Bid (Size) 12.74 (8)
Ask (Size) 12.75 (1)
Prev. Close 12.83
Today's Range 12.66 - 12.89
52wk Range 5.910 - 13.62
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec. 
Via Benzinga
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
From Amicus Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
+6.87%
+6.87%
1 Month
+4.42%
+4.42%
3 Month
+27.50%
+27.50%
6 Month
+29.84%
+29.84%
1 Year
+35.49%
+35.49%

More News

Read More
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via Globe NewsWire
FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy
Via Benzinga
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Recap: Amicus Therapeutics Q3 Earnings
Via Benzinga
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
From Amicus Therapeutics, Inc.
Via Globe NewsWire
Amicus Therapeutics Announces Participation at World Muscle Society 2022
From Amicus Therapeutics, Inc.
Via Globe NewsWire
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Via Benzinga
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
Via Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Via Benzinga
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
Via Benzinga
PayPal, SoFi Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Via Benzinga
Short Volatility Alert: Amicus Therapeutics, Inc.
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Via Benzinga
7 Biotech Stocks With Key Catalysts for May
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.